ANI Pharmaceuticals (NASDAQ:ANIP) announced that following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application, the company launched Estradiol Gel, 0.06% ...

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- (ANI or the Company) (Nasdaq: ANIP) today announced that following final ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will present new pre-clinical data highlighting its membranous nephropathy (MN) research during two ...

ANI Pharmaceuticals acquired Alimera Sciences, boosting its rare disease segment with a couple of durable ophthalmology ...

Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $62 from $60 and keeps a Hold rating on the shares as ...

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its price objective lifted by equities researchers at Truist Financial from $60.00 to $62.00 in a report released on Tuesday, Benzinga reports.

Ratings for ANI Pharmaceuticals ANIP were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings ...

Piper initiated with an Overweight rating and a price target of $68. Earlier this year, ANI Pharmaceuticals acquired Alimera Sciences for $5.50 per share in cash and one non-tradable contingent ...

ANI Pharmaceuticals (NASDAQ:ANIP) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

View ANI Pharmaceuticals, Inc. (ANIP) current and estimated P/E ratio data provided by Seeking Alpha.

ANI Pharmaceuticals (ANIP) announced that following final approval from the U.S. FDA for its Abbreviated New Drug Application, the company ...